SLC5A2 and type 1 diabetes mellitus: Due to their unique mechanism of action, SGLT2 inhibitors can be combined with other glucose-lowering agents, including insulin, and often reduce the required insulin dosage in both Type 2 and Type 1 diabetes [30,31].